<p>A new class of lower-cost alternatives to brand name drugs has emerged: biosimilars. With the development of new technology, we have new complications for antitrust litigation and to explore these issues and more Nathan, Steve, and Brent are joined by antitrust expert Catia Twal.</p>

A new class of lower-cost alternatives to brand name drugs has emerged: biosimilars. With the development of new technology, we have new complications for antitrust litigation and to explore these issues and more Nathan, Steve, and Brent are joined by antitrust expert Catia Twal.

52. Prescription for Competition: Biosimilars are Changing Antitrust

Engaging, insightful, fun! Say hello to a fresh perspective on numbers with our hosts, Edgeworth Economics experts Dr. Steve Bronars, Dr. Nathan Woods, and Brent Butgereit, as they break down what’s happening in our current economic landscape and what they think about the figures that are important in our work and daily lives. Twentyish minutes of navigating the madness in the methods, every two weeks. We hope you walk away a bit better informed for your work, in your studies, or even at your next party.

Share 52. Prescription for Competition: Biosimilars are Changing Antitrust

Sign up to save your podcasts

52. Prescription for Competition: Biosimilars are Changing Antitrust

52. Prescription for Competition: Biosimilars are Changing Antitrust